Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer

In patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC), atezolizumab therapy improves survival with manageable safety. The open-label, single-arm phase III/IV TAIL study (NCT03285763) evaluated atezolizumab monotherapy in patients with previously treated NSCLC,...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jinming Yu, Andrea Ardizzoni, Delvys Rodriguez-Abreu, Sergio Azevedo, Belen Rubio-Viqueira, Jorge Alatorre-Alexander, Hans J M Smit, Konstantinos Syrigos, Jonathan Tolson, Thomas Newsom-Davis, Elen Höglander, Monika Kaul, Youyou Hu, Hans Kristian Vollan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2022-11-01
coleção:	Journal for ImmunoTherapy of Cancer
Acesso em linha:	https://jitc.bmj.com/content/10/11/e005581.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!